1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > World CNS Therapeutics Industry

World CNS Therapeutics Industry

  • February 2015
  • -
  • Global Industry Analysts
  • -
  • 482 pages

This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 145 companies including many key and niche players such as -

AbbVie Inc.
Actavis Plc
Alkermes Plc
Amneal Pharmaceuticals, LLC
Aspen Pharmacare Holdings Limited

Table Of Contents

World CNS Therapeutics Industry



I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3
Anti-Alzheimer's Drugs I-3
Anti-Parkinson's Drugs I-4
Anti-Epilepsy Drugs I-4
Pain Management Drugs I-4
Anti-Psychotics Drugs I-5
Bipolar disorder I-5
Schizophrenia I-5
Anti-Depressants Drugs I-5
Others I-6
Attention Deficit Hyperactivity Disorder I-6
Multiple Sclerosis I-6
Insomnia I-6


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
CNS Therapeutics Exhibit Robust Opportunities amidst Rising
Incidence of CNS Disorders II-1
Patent Expiries of Major Drugs Exert Downward Pressure on the
Global CNS Market II-2
Patent Expiries of Leading CNS Drugs: 2008-2022 II-3
Aging Demographics and Improved Diagnosis Drive Market Growth II-4
Table 1: Global Population Statistics for the 65+ Age Group
(2012) (includes corresponding Graph/Chart) II-5

Table 2: Percentage Share Breakdown of Global Population by
Age Group, Worldwide: 2025 (includes corresponding
Graph/Chart) II-6
Increased Spending on Prescription Drugs Bodes Well for the
CNS Therapeutics Market II-6
Key Statistical Data: II-7
Table 3: Global Spending on Prescription Drugs by Country
(2014): Percentage Share Breakdown of Dollar Spending
(includes corresponding Graph/Chart) II-7

Table 4: Per Capita Healthcare Expenditure in US$ by Select
Country (includes corresponding Graph/Chart) II-8

Table 5: Healthcare Expenditure as % of GDP by Select
Country (includes corresponding Graph/Chart) II-9
Developed Markets to Maintain their Dominance II-10
Developing Market to Drive the Market Momentum II-10

2. NOTEWORTHY MARKET TRENDS, GROWTH DRIVERS and ISSUES II-12
Growing Penetration of Generic Drugs Emerges as a Key Trait II-12
Table 6: Global Spending on Generic Drugs Vis-a-vis Branded
Drugs (2013 and 2018): Percentage Share Breakdown of Dollar
Spending by Drug Category (includes corresponding
Graph/Chart) II-12

Table 7: Spending on Prescription Medicines in Developed
Economies (2013 and 2018): Percentage Share Breakdown of Dollar
Spending by Drug Category (includes corresponding
Graph/Chart) II-13

Table 8: Spending on Prescription Medicines in Developing
Economies (2013 and 2018): Percentage Share Breakdown of Dollar
Spending by Drug Category (includes corresponding
Graph/Chart) II-13
Developments in CNS Drug Delivery Technologies Bode Well for
the CNS Drugs Market II-14
Understanding of BBB Cell Biology and Its Positive Impact on
Epilepsy Drugs: A Case-in-Point II-14
Branded Generic CNS Drugs: A Key Revenue Spinner in Emerging
Countries II-14
Pharma Companies: Seeking New Tools to Offset Pressure on Drug
Pipelines II-15
Awareness Campaigns Launched by Pharma Companies to Benefit
the Market II-16
China's Growing Role to Help Global CNS Therapeutics Market
Make Significant Gains II-16
Select Available and Pipeline CNS Drugs in China II-17
Select Anti-Schizophrenia Drugs Available in China II-18
Other Available CNS Drugs in China II-18
Select Pipeline CNS Drugs in China II-18
Key Challenges II-18
Healthcare Cost Rationing and Government Caps Challenge Branded
CNS Drugs II-18
Drug Trial Failures Continue to Hamper Neuroscience Research
and the Overall Market Prospects II-19

3. MARKET ANALYSIS BY THERAPEUTIC CATEGORIES II-21
Anti-Epilepsy Market II-21
Market Overview II-21
Table 9: Epilepsy Incidence by Type (2014): Percentage Share
Breakdown for Idiopathic and Symptomatic Epilepsy (includes
corresponding Graph/Chart) II-21

Table 10: Symptomatic Epilepsy Incidence by Type (2014):
Percentage Share Breakdown of Congenital, Degenerative,
Infective, Neoplastic, Trauma, and Vascular Epilepsy
(includes corresponding Graph/Chart) II-22
Treatment II-22
Anti-Epileptic Market (AEDs) by Drug Class: List of Drugs
under Broad-Spectrum AEDs and Narrow-Spectrum AEDs II-23
Leading Anti-Epileptic Drugs II-23
Leading Anti-Epileptic Drugs and Their Mechanism of Action II-24
Patent Expiries of Major Anti- Epilepsy Drugs II-24
High Unmet Needs Offer Scope for Market Growth II-25
Select Currently Available Epilepsy Drugs II-25
Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials II-27
Innovative Drugs Needed for Better Treatment Compliance II-27
Abounding Potential for NCEs II-28
Developed Countries Account for a Major Share of Epilepsy
Treatment II-28
Table 11: The US Epilepsy Market by Drug Category (2014):
Percentage Market Share Breakdown of Total Prescriptions for
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin,
Topiramate, and Others (includes corresponding Graph/Chart) II-29
Developing Countries Struggle with Low Treatment Rates II-29
Refractory Childhood Epilepsy and Pregnancy Epilepsy - Major
Concerns II-29
Review of Anti-Epilepsy Drugs II-30
Vimpat® II-30
Keppra® II-30
Lamictal II-31
Tegretol® II-31
Sabril® II-31
Perampanel II-31
Zonegran® II-31
Topamax® II-32
Trileptal® II-32
Neurontin® II-32
Lyrica® II-32
Depakine® II-32
CNS Pain Management II-33
Market Overview II-33
Drugs Indicated for Pain Management II-34
Combination Therapies Gain Prominence II-34
Neuropathic Pain Management: Market with High Potential II-35
Migraine Market: A Core Vertical in CNS Pain Management II-35
Migraine Care: Select Patent Expiries (2013-2015) II-36
Select Pain Management Drugs II-36
Flupirtine II-36
Lyrica® II-36
Oxycodone II-36
Nucynta ER II-36
Metabotropic Glutamate Receptors (mGluRs) II-36
Anti-Alzheimer's II-37
Market Overview II-37
Table 12: Alzheimer's Prevalence by Age Group (includes
corresponding Graph/Chart) II-38
Treatment for Alzheimer's II-38
Select Leading Drugs for Alzheimer's Disease by Drug Category II-38
Patent Expiries of Leading Alzheimer's Drugs II-38
Table 13: Alzheimer's Leading Drug Sales (in US$ Million):
2012 (includes corresponding Graph/Chart) II-39
Promising Pipeline Drugs to Elevate Future AD Treatment II-39
Pipeline Drugs for Alzheimer's Disease II-40
A Review of Select Anti-Alzheimer's Drugs II-42
Aricept II-42
Exelon II-42
Reminyl II-43
Ebixa II-43
Namenda II-43
Anti-Parkinson's II-43
Market Overview II-43
Levodopa - The “Gold Standard” for Parkinson's Treatment II-44
Table 14: Global Anti-Parkinson's Drugs Market by Leading
Drugs (2014): Percentage Share Breakdown for Revenues by
Drug Category (includes corresponding Graph/Chart) II-44

Table 15: Percentage Share Breakdown of Revenues for
Levodopa Franchise in the US: 2013 (includes corresponding
Graph/Chart) II-45
Pipeline Drugs for Parkinson's Diseases: As on August, 2013 II-45
Select Anti-Parkinson's Drugs II-45
Levodopa II-45
Dopamine Agonists II-45
Mirapex II-46
Requip II-46
Anti-Depressants II-46
Market Overview II-46
Pipeline Anti-Depressant Drugs II-47
Select Antidepressants Drugs II-48
Zoloft (Sertraline) II-48
Cymbalta® II-48
Prozac (Fluoxetine) II-48
Effexor (Venlafaxine) II-48
Paxil II-48
Wellbutrin (Bupropion) II-48
Anti-Psychotics II-49
Market Overview II-49
Table 16: Global Antipsychotics Market by Leading Brand
(2014): Percentage Market Share Breakdown of Revenues for
Abilify, Geodon, Invega, Invega Sustenna, Risperdal,
Risperdal Consta, Seroquel, Zyprexa, and Others (includes
corresponding Graph/Chart) II-50
Prevalence of Schizophrenia and Bipolar Disorders:
Statistical Snippets II-50
Second Generation Antipsychotics Beset with Safety Issues II-50
Companies Focus on Next Generation Products to Deflect the
Heat of Competition II-51
Pipeline Drugs for Schizophrenia and Bipolar disorders II-52
Select Anti-Psychotic Drugs II-53
Zyprexa II-53
Seroquel II-53
Abilify II-54
Clozaril II-54
Risperdal II-54
Risperdal® Consta® II-54
Geodon II-55
Invega Sustenna II-55
Saphris II-55
Latuda II-55
Other CNS Disorders II-56
Attention Deficit Hyperactivity Disorder (ADHD) II-56
Market Overview II-56
Pipeline Drugs for ADHD II-56
Select ADHD Drugs II-58
Concerta II-58
Strattera II-58
Adderall II-58
Multiple Sclerosis (MS) II-58
Table 17: Global Multiple Sclerosis Market by Leading Brand
(2014): Percentage Market Share Breakdown of Revenues for
Copaxone, Avonex, Tysabri, Tecfidera, Gilenya, Betaseron,
Rebif, Aubagio, and Others (includes corresponding
Graph/Chart) II-59
Multiple Sclerosis Approved Therapies (Injectables) II-59
Multiple Sclerosis Approved Therapies (Oral) II-60
Efficacy of Injectable MS Drugs II-60
Efficacy of Oral MS Drugs II-60
Patent Expiration Date/Year of the Major MS Drugs II-60
Tecfidera to Further Strengthen Biogen's Leadership II-61
Increased Focus on Reducing the Frequency of Administration II-61
Route and Dosing Frequency of Injectable Multiple Sclerosis
Products II-61
MS Pipeline II-61
Table 18: Multiple Sclerosis Market: Drugs under
Development (includes corresponding Graph/Chart) II-62
Select Pipeline MS Drugs II-62
Established Players Witness Decline in Sales II-63
Insomnia II-63
Overview II-63
Select Pipeline Insomnia Drugs II-63
Zolpidem II-64
Eszopiclone II-64
Other Noteworthy CNS Pipeline Drugs II-64

4. PRODUCT OVERVIEW II-67
Definition II-67
Central Nervous System II-67
Mortality Threat of CNS Disorders II-67
Science of NMDA Receptors and its Disease Significance II-67
Major CNS Disorders: II-68
Alzheimer's Disease II-68
Alzheimer's Affect on Brain II-68
Causes for Alzheimer's II-69
Who Are at Risk? II-69
Prevalence of Alzheimer's Disease II-70
Diagnosis of Alzheimer's II-70
Parkinson's Disease II-70
Prevalence II-71
Symptoms II-71
Causes II-71
Diagnosis II-72
Epilepsy II-72
Symptoms of Epilepsy II-73
Types of Epilepsy and Epileptic Seizures II-73
Preventive Measures II-73
Treatment Options for Epilepsy Patients II-73
Treatment Options Available for Epilepsy Patients II-74
Epilepsy Drug Treatment Paradigm II-74
Pain Management II-75
Debilitating Effects of Pain II-75
Types of Pain II-75
Acute Pain II-75
Chronic Pain II-76
Migraine II-76
Neuropathic Pain II-76
Nociceptive Pain II-76
Anti-Psychotics II-77
Bipolar Disorder II-77
Symptoms of Bipolar Disorder II-77
Mood Episode - A Major Symptom II-77
Manic Episode Vs Depressive Episode II-78
Causes of Bipolar Disorder II-78
Types of Bipolar Disorder II-78
Co-morbidities of Bipolar Disorder II-79
Schizophrenia II-79
Prevalence by Gender II-79
Symptoms of Schizophrenia II-80
Causes of Schizophrenia II-81
Therapies for Bipolar Disorder and Schizophrenia II-81
Mood Stabilizing Agents II-81
Antidepressants II-82
Antipsychotic Drugs II-82
Indications of Antipsychotics II-83
An Effective Adjunctive Therapy II-83
Off-label Uses II-83
Efficacy - Marred by Lack of Evidence Base II-83
Types of Antipsychotics II-84
Difference between Typical and Atypical II-84
Atypical Antipsychotics Up Against Typicals II-84
Side Effects of Antipsychotics II-85
Symptoms of Antipsychotics Withdrawal II-86
Controversies Surrounding Antipsychotics II-87
Prohibited Practices II-87
Antipsychotics in Pregnant Women II-87
Depression II-88
Prevalence of Depression II-88
Causes of Depression II-88
Types of Depressive Disorders II-88
Available Treatment II-89
Tricyclic Antidepressants II-89
Monoamine Oxidase Inhibitors II-89
Lithium Salts II-89
Working of Antidepressants II-89
Ranking of Antidepressants in Terms of Efficacy II-90
Types of Antidepressants II-90
NMDA Receptor Antagonists II-90
NMDA Receptor (NMDAR) II-90
NMDA Receptor Agonists II-90
Acetylcholinesterase Inhibitors II-91
Selective Serotonin Reuptake Inhibitors (SSRIs) II-91
Workings of SSRIs II-91
Safety Levels of SSRI Drugs II-92
Adverse Effects of SSRI II-92
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) II-92
Others Common CNS Disorders II-93
Attention Deficit Hyperactivity Disorder II-93
Consequences of ADHD II-93
What Leads to ADHD? II-93
Treating ADHD II-93
Multiple Sclerosis (MS) II-94
Types of Multiple Sclerosis II-94
Table 19: Clinical Subtypes of Multiple Sclerosis (MS)
(includes corresponding Graph/Chart) II-95
Prevalence of MS II-95
Causes of MS II-95
Myths Surrounding Multiple Sclerosis II-96
Symptoms of MS II-96
Diagnosis of MS II-96
Treatment II-96
Insomnia II-96
Prevalence of Insomnia II-96
Therapies for Insomnia II-97

5. PRODUCT INTRODUCTIONS/INNOVATIONS and RandD BREAKTHROUGHS II-98
Eisai Unveils AMPA Receptor Antagonist Fycompa (Perampanel) II-98
Watson Pharmaceuticals Rolls Out REPREXAINâ„¢ CIII II-98
INSYS Therapeutics Launches SUBSYSâ„¢ for BTCP Treatment II-98
Omron Healthcare Unveils Omron electroTHERAPY Pain Relief Unit II-98
Sun Pharma, Lupin and Dr Reddy's Introduce Generic
Schizophrenia Drug II-98
Mylan Launches Levetiracetam in Sodium Chloride Injection II-99
Dr. Reddy's Laboratories Introduces Geodon II-99
Sun Pharmaceutical Unveils Zyprexa Zydis II-99
H Lundbeck Introduces Onfi Anti-Epileptic Drug in US II-99
Eisai and Nobelpharma to Introduce Fostoin Anticonvulsant Agent II-99
Eisai Europe Launches Zebinix® Eslicarbazepine Acetate II-99
Eisai Launches Fycompa II-99
H. Lundbeck Introduces Sycrest II-100
GW Pharmaceuticals to Develop Cannabis-Based Epileptic Treatment II-100
Teva Pharmaceutical Industries Introduces Quetiapine and
Quetiapine XL II-100
Eisai to Unveil Zonegran Drug Treatment in Russia II-100

6. RECENT INDUSTRY ACTIVITY II-101
Actavis Takes Over Forest Laboratories II-101
Teva Pharmaceutical Snaps Up Labrys II-101
Teva Pharmaceutical Acquires NuPathe II-101
Alkermes Announces New Developments for ALKS 5461 and
Aripiprazole Lauroxil II-101
Allergan Receives FDA Rejection for Semprana II-101
Mallinckrodt Receives FDA Approval for PENNSAID 2% Formulation II-101
Takeda Pharmaceutical to Redesign its Global Organizational
Structure II-101
Boehringer Ingelheim Teams Up with Hydra Biosciences II-102
BIAL Signs Exclusive Licensing Agreement with moksha8 II-102
Actavis and Adamas Pharmaceuticals Receive USFDA Approval for
NDA for Namzaric II-102
IntelGenx and RedHill Biopharma Receive USFDA's CRL for
VersaFilmâ„¢ Oral Film Product II-102
Alkermes Achieves Positive Phase I Results for ALKS 3831 II-102
Teva Pharmaceutical Industries to Disclose Study Results for
AZILECT® Rasagiline Tablets II-102
Johnson and Johnson Pays Fine for Illegal Marketing II-103
Perrigo Takes Ove Elan II-103
Lundbeck Expands Collaboration with Otsuka II-103
Eisai Receives Finnish Approval for Fycompa II-103
Sunovion Files two sNDAs for Latuda® II-103
Mylan Pharmaceuticals Receives FDA Approval for Lithium
Carbonate Extended-release Tablets USP II-103
Supernus Obtains Approval for Oxtellar XR Anti-Epilepsy Drug II-104
FDA Delays the Launch of Antipsychotic Drug by Otsuka and
Lundbeck II-104
Forest Laboratories Submits NDA for Cariprazine II-104
GSK Agrees to Pay Criminal Fine for Illegal Promotion II-104
Novartis Discontinues Development of Fanapt II-104
Qualitest Pharmaceuticals Obtains FDA Approval for
Levetiracetam Tablets II-104
Prasco Laboratories Inks Agreement with Shire II-105
Par Pharmaceutical and Handa Pharmaceuticals Ink Licensing
Agreement II-105
Zogenix Inks Exclusive Co-Promotion Agreement with Mallinckrodt II-105
Actavis Signs Agreement with QrxPharma to Market MOXDUO® IR II-105
Mallinckrodt Receives FDA Approval for EXALGO® Tablet II-105
Pfizer Receives FDA Approval for Lyrica® Capsules II-105
Sunovion Files for Expanded Use of Latuda® II-105
Glenmark Generics Obtains FDA Approval for Lamotrigine II-106
Mylan Obtains FDA Approval for Levetiracetam Extended-Release
Tablets II-106
Mallinckrodt Acquires CNS Therapeutics II-106
Neurodyn Takes Over NeuroQuest II-106
Paladin Labs and QRxPharma Sign Licensing Agreement II-106
Sanofi and Alfresa Pharma Ink Agreement to Develop Vigabatrin II-106
Otsuka Files for Additional Indication for Abilify® II-107
UCB and Otsuka Pharmaceuticals to Develop Anti-Epileptic Drugs II-107
Eisai Receives Manufacturing License in the UK II-107
Dainippon Sumitomo and Takeda Receive Acceptance from the EMA II-107
Dainippon Sumitomo Inks an Agreement with Takeda II-107
Aspen Global to Take Over Drug Portfolio of GlaxoSmithKline II-107
Upsher-Smith Laboratories Takes Over Proximagen Group II-108
Eisai Receives Approval for Fycompa Drug II-108
UCB Discloses Epilepsy Drug Trial Results II-108
Eisai Europe Obtains Approval for Zonegran® Anti-Epileptic Agent II-108
Forest Laboratories Enters into Broad Strategic Alliance with
moksha8 II-108
Moksha8 Extends License Agreement with Watson Pharmaceuticals II-108

7. FOCUS ON SELECT GLOBAL PLAYERS II-109
AbbVie Inc. (USA) II-109
Actavis Plc. (Ireland) II-109
Alkermes Plc. (Ireland) II-109
Amneal Pharmaceuticals, LLC (USA) II-110
Aspen Pharmacare Holdings Limited (Australia) II-111
AstraZeneca Plc (UK) II-111
BIAL Group (Portugal) II-112
Boehringer Ingelheim GmbH (Germany) II-113
Bristol-Myers Squibb (USA) II-113
Dainippon Sumitomo Pharma Co., Ltd. (Japan) II-114
Eisai Co., Ltd. (Japan) II-115
Eli Lilly and Co. (USA) II-116
F. Hoffmann-La Roche Ltd. (Switzerland) II-116
Fabre-Kramer Pharmaceuticals, Inc. (USA) II-117
GlaxoSmithKline (UK) II-117
H. Lundbeck A/S (Denmark) II-118
Johnson and Johnson (USA) II-118
Janssen Pharmaceuticals, Inc. (USA) II-119
Merck and Co., Inc. (USA) II-120
Neurocrine Biosciences, Inc. (USA) II-120
Novartis AG (Switzerland) II-120
Otsuka Pharmaceutical Co., Ltd. (Japan) II-121
Pfizer, Inc. (USA) II-122
Sanofi S.A (France) II-123
Shire Plc (UK) II-124
Sunovion Pharmaceuticals, Inc. (USA) II-125
Takeda Pharmaceutical Co., Ltd. (Japan) II-125
Teva Pharmaceutical Industries Ltd. (Israel) II-126
UCB Group (Belgium) II-126

8. GLOBAL MARKET PERSPECTIVE II-127
Table 20: World Recent Past, Current and Future Analysis for CNS
Therapeutics by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2014 through 2020 (includes corresponding Graph/Chart) II-127

Table 21: World Historic Review for CNS Therapeutics by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Latin America and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2007 through 2013
(includes corresponding Graph/Chart) II-128

Table 22: World 14-Year Perspective for CNS Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, Latin America and
Rest of World Markets for Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) II-129

Table 23: World Recent Past, Current and Future Analysis for
Anti-Alzheimer's by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2014 through 2020 (includes corresponding Graph/Chart) II-130

Table 24: World Historic Review for Anti-Alzheimer's by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Latin America and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2007 through 2013
(includes corresponding Graph/Chart) II-131

Table 25: World 14-Year Perspective for Anti-Alzheimer's by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, Latin America and
Rest of World Markets for Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) II-132

Table 26: World Recent Past, Current and Future Analysis for
Anti-Parkinson's by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2014 through 2020 (includes corresponding Graph/Chart) II-133

Table 27: World Historic Review for Anti-Parkinson's by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Latin America and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2007 through 2013
(includes corresponding Graph/Chart) II-134

Table 28: World 14-Year Perspective for Anti-Parkinson's by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, Latin America and
Rest of World Markets for Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) II-135

Table 29: World Recent Past, Current and Future Analysis for
Anti-Epilepsy by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2014 through 2020 (includes corresponding Graph/Chart) II-136

Table 30: World Historic Review for Anti-Epilepsy by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Latin America and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2007 through 2013
(includes corresponding Graph/Chart) II-137

Table 31: World 14-Year Perspective for Anti-Epilepsy by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, Latin America and
Rest of World Markets for Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) II-138

Table 32: World Recent Past, Current and Future Analysis for
Pain Management by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2014 through 2020 (includes corresponding Graph/Chart) II-139

Table 33: World Historic Review for Pain Management by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Latin America and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2007 through 2013
(includes corresponding Graph/Chart) II-140

Table 34: World 14-Year Perspective for Pain Management by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, Latin America and
Rest of World Markets for Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) II-141

Table 35: World Recent Past, Current and Future Analysis for
Anti-Psychotics by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2014 through 2020 (includes corresponding Graph/Chart) II-142

Table 36: World Historic Review for Anti-Psychotics by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Latin America and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2007 through 2013
(includes corresponding Graph/Chart) II-143

Table 37: World 14-Year Perspective for Anti-Psychotics by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, Latin America and
Rest of World Markets for Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) II-144

Table 38: World Recent Past, Current and Future Analysis for
Anti-Depressants by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2014 through 2020 (includes corresponding Graph/Chart) II-145

Table 39: World Historic Review for Anti-Depressants by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Latin America and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2007 through 2013
(includes corresponding Graph/Chart) II-146

Table 40: World 14-Year Perspective for Anti-Depressants by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, Latin America and
Rest of World Markets for Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) II-147

Table 41: World Recent Past, Current and Future Analysis for
Others by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2014 through 2020 (includes corresponding Graph/Chart) II-148

Table 42: World Historic Review for Others by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific, Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2007 through 2013
(includes corresponding Graph/Chart) II-149

Table 43: World 14-Year Perspective for Others by Geographic
Region - Percentage Breakdown of Value Sales for US, Canada,
Japan, Europe, Asia-Pacific, Latin America and Rest of World
Markets for Years 2007, 2015 and 2020 (includes corresponding
Graph/Chart) II-150


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
The Largest CNS Therapeutics Market Globally III-1
Aging Population: A Strong Demographic Driver III-1
Table 44: North American Elderly Population by Age Group
(1975-2050) (includes corresponding Graph/Chart) III-2

Table 45: The US Population Breakdown by Age Group (2014)
(includes corresponding Graph/Chart) III-2
Patent Expiries Curtail Market Growth III-3
Patent Expiries of Leading CNS Drugs in the US III-3
Focus on Select Markets III-4
Alzheimer's Market III-4
NAPA Grants Help AD Research III-4
Anti-Epilepsy Market III-4
Epilepsy - A Major Concern for the Healthcare Industry III-4
A Glance at Epilepsy Statistics III-5
Anti-Epilepsy Drugs III-5
Table 46: The US Epilepsy Drugs Market by Type (2014):
Percentage Market Share Breakdown of Sales for
Levetiracetam, Lamotrigine, Topiramate, Gabapentin,
Pregabalin, and Others (includes corresponding
Graph/Chart) III-6

Table 47: The US Epilepsy Drugs Market by Leading Brand
(2012 and 2018): Percentage Market Share Breakdown of Total
Prescriptions for Dilantin, Neurontin, Depakote; and
Other Seizure Therapeutics (includes corresponding
Graph/Chart) III-6
The US Epilepsy Market: Patent Expiry of Select Major Drugs III-7
Epilepsy in Children III-7
Growing Competition from Generics III-7
Pain Management Market III-8
Table 48: The US Pain Management Market by Leading Player
(2014): Percentage Market Share Breakdown of Revenues for
Endo, Purdue, Johnson and Johnson Co., Pfizer, Teva, and
Others (includes corresponding Graph/Chart) III-8
Neuropathic Pain Market III-8
Anti-Psychotic Drugs Market III-9
Mental Illnesses - Epidemiology III-9
Facts and Figures III-9
Table 49: Lifetime Prevalence (%) of Bipolar Disorder in
the US Population by Age Group (includes corresponding
Graph/Chart) III-10
Popular Antipsychotic Drugs in the US III-10
Anti-Psychotic Drugs by FDA Approved Age and Indication
in the US III-10
Table 50: The US Anti-Psychotic Drugs Market (2014):
Percentage Share Breakdown of Value Sales by Indication
(includes corresponding Graph/Chart) III-11

Table 51: The US Antipsychotics Market (2014):
Percentage Share Breakdown of Prescriptions by
Indication (includes corresponding Graph/Chart) III-11

Table 52: The US Atypical Antipsychotic Market by
Leading Brand (2014): Percentage Market Share Breakdown
of Revenues for Abilify, Invega, Invega Sustenna,
Risperdal Consta, Seroquel, Zyprexa, and Others
(includes corresponding Graph/Chart) III-11

Table 53: The US Antipsychotic Long-Acting Injectables
Market by Leading Drugs (2014): Percentage Market Share
Breakdown of Total Prescriptions for Risperdal Consta,
Invega Sustenna, Abilify Maintena, and Others (includes
corresponding Graph/Chart) III-12
Growth Dampeners III-12
Surging Off-label Prescriptions III-12
Advertising for Antipsychotics Acquires a Whole New Dimension III-12
Illegal Marketing - A Cause of Concern for Governments III-13
Generics Occupy Front Seat III-13
Initiatives by Regulatory Bodies Favor Generics III-13
Initiatives to Cut Spending on Antipsychotics III-14
Antipsychotics Use in Nursing Homes Raises Concern III-14
Rising Antipsychotic Use among Children - A Cause of Concern III-15
ADHD Market III-15
Select Available ADHD Drugs in the US III-16
Table 54: The US ADHD Drugs Market by Leading Brands
(2014): Percentage Share Breakdown of Total Prescription
Sales for Adderall XR, Intuniv, Vyvanse, and Others
(includes corresponding Graph/Chart) III-16

Table 55: The US Non-Stimulant ADHD Market by Leading
Brand (2014): Percentage Share Breakdown of Prescription
Sales for Intuniv, Strattera, and Others (includes
corresponding Graph/Chart) III-16

Table 56: The US ADHD Drugs Market by Drug Category
(2014): Percentage Share Breakdown of Total Prescription
Sales for Stimulants (Amphetamines and Methylphenidates)
and Non-Stimulants (includes corresponding Graph/Chart) III-17

Table 57: The US ADHD Drugs Market by Type (2014):
Percentage Share Breakdown of Total Prescription Sales
for Branded and Generic Drug Groups (includes corresponding
Graph/Chart) III-17
Adult ADHD Drugs Continue to Widen their Share III-17
Table 58: The US ADHD Drugs Market by Drug Category
(2014): Percentage Share Breakdown of Total Prescriptions
for Adult and Pediatric Patient Groups (includes
corresponding Graph/Chart) III-17
Product Launches III-18
Strategic Corporate Developments III-19
Select Key Players III-24
B.Market Analytics III-31
Table 59: The US Recent Past, Current and Future Analysis for
CNS Therapeutics by Product Segment - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants, and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-31

Table 60: The US Historic Review for CNS Therapeutics by
Product Segment - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants, and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2013 (includes corresponding Graph/Chart) III-32

Table 61: The US 14-Year Perspective for CNS Therapeutics by
Product Segment - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants, and Other
Markets for Years 2007, 2015 and 2020 (includes corresponding
Graph/Chart) III-33

2. CANADA III-34
A.Market Analysis III-34
CNS Diseases: Facts and Figures III-34
Strategic Corporate Developments III-34
B.Market Analytics III-35
Table 62: Canadian Recent Past, Current and Future Analysis
for CNS Therapeutics by Product Segment - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants, and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-35

Table 63: Canadian Historic Review for CNS Therapeutics by
Product Segment - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants, and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2013 (includes corresponding Graph/Chart) III-36

Table 64: Canadian 14-Year Perspective for CNS Therapeutics
by Product Segment - Percentage Breakdown of Dollar Sales
for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants, and Other
Markets for Years 2007, 2015 and 2020 (includes corresponding
Graph/Chart) III-37

3. JAPAN III-38
A.Market Analysis III-38
Graying Population Spurs Growth of CNS Therapeutics III-38
Table 65: Japanese Elderly (65+ Years) Population:
2000-2020 (includes corresponding Graph/Chart) III-38
Product Launch III-38
Strategic Corporate Developments III-39
Select Key Players III-39
B.Market Analytics III-42
Table 66: Japanese Recent Past, Current and Future Analysis
for CNS Therapeutics by Product Segment - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants, and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-42

Table 67: Japanese Historic Review for CNS Therapeutics by
Product Segment - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants, and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2013 (includes corresponding Graph/Chart) III-43

Table 68: Japanese 14-Year Perspective for CNS Therapeutics
by Product Segment - Percentage Breakdown of Dollar Sales
for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants, and Other
Markets for Years 2007, 2015 and 2020 (includes corresponding
Graph/Chart) III-44

4. EUROPE III-45
A.Market Analysis III-45
Ageing Population Boosts Demand III-45
Table 69: European Country-wise Statistics of 60+
Population as % of Total Population: 2013 (includes
corresponding Graph/Chart) III-46
European Patent Expiries of Select CNS Drugs III-47
Pain Management Market III-47
Neuropathic Pain Market Witnesses Foray of Generics III-47
Anti-Psychotics Market III-48
Demand for Antipsychotics for Bipolar Disorder Upbeat III-48
Generics to Witness Growth in Bipolar Disorder Therapeutics
Market III-49
B.Market Analytics III-50
Table 70: European Recent Past, Current and Future Analysis
for CNS Therapeutics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2014 through 2020 (includes corresponding Graph/Chart) III-50

Table 71: European Historic Review for CNS Therapeutics by
Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2007 through 2013
(includes corresponding Graph/Chart) III-51

Table 72: European Recent Past, Current and Future Analysis
for CNS Therapeutics by Product Segment - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants, and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-52

Table 73: European Historic Review for CNS Therapeutics by
Product Segment - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants, and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2013 (includes corresponding Graph/Chart) III-53

Table 74: European 14-Year Perspective for CNS Therapeutics
by Geographic Region - Percentage Breakdown of Value Sales
for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) III-54

Table 75: European 14-Year Perspective for CNS Therapeutics
by Product Segment - Percentage Breakdown of Dollar Sales
for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants, and Other
Markets for Years 2007, 2015 and 2020 (includes corresponding
Graph/Chart) III-55

4a. FRANCE III-56
A.Market Analysis III-56
Product Launch III-56
Sanofi S.A - A Key French Player III-56
B.Market Analytics III-58
Table 76: French Recent Past, Current and Future Analysis for
CNS Therapeutics by Product Segment - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants, and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-58

Table 77: French Historic Review for CNS Therapeutics by
Product Segment - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants, and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2013 (includes corresponding Graph/Chart) III-59

Table 78: French 14-Year Perspective for CNS Therapeutics by
Product Segment - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants, and Other
Markets for Years 2007, 2015 and 2020 (includes corresponding
Graph/Chart) III-60

4b. GERMANY III-61
A.Market Analysis III-61
Strategic Corporate Development III-61
Boehringer Ingelheim GmbH - A Key German Player III-61
B.Market Analytics III-62
Table 79: German Recent Past, Current and Future Analysis for
CNS Therapeutics by Product Segment - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants, and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-62

Table 80: German Historic Review for CNS Therapeutics by
Product Segment - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants, and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2013 (includes corresponding Graph/Chart) III-63

Table 81: German 14-Year Perspective for CNS Therapeutics by
Product Segment - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants, and Other
Markets for Years 2007, 2015 and 2020 (includes corresponding
Graph/Chart) III-64

4c. ITALY III-65
A.Market Analysis III-65
Market Snapshots III-65
B.Market Analytics III-66
Table 82: Italian Recent Past, Current and Future Analysis for
CNS Therapeutics by Product Segment - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants, and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-66

Table 83: Italian Historic Review for CNS Therapeutics by
Product Segment - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants, and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2013 (includes corresponding Graph/Chart) III-67

Table 84: Italian 14-Year Perspective for CNS Therapeutics
by Product Segment - Percentage Breakdown of Dollar Sales
for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants, and Other
Markets for Years 2007, 2015 and 2020 (includes corresponding
Graph/Chart) III-68

4d. THE UNITED KINGDOM III-69
A.Market Analysis III-69
Nice Recommendations on CNS Therapeutics III-69
Product Launches III-69
Strategic Corporate Developments III-70
Select Key Players III-71
B.Market Analytics III-74
Table

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Future Horizons and Growth Strategies in the Global Orthopedics Market 2015: Strategic Assessments of  Leading Suppliers

Future Horizons and Growth Strategies in the Global Orthopedics Market 2015: Strategic Assessments of Leading Suppliers

  • $ 12 500
  • Industry report
  • June 2015
  • by Venture Planning Group

Complete report $12,500.  Individual company assessments $1,900. A strategic assessment of the competitive environment is unquestionably one of the highest priority management responsibilities, the task ...

EUROPE (15 Countries) MARKETS FOR SOFT TISSUE REINFORCEMENT AND REGENERATION - 2011-2021

EUROPE (15 Countries) MARKETS FOR SOFT TISSUE REINFORCEMENT AND REGENERATION - 2011-2021

  • $ 9 995
  • Industry report
  • April 2015
  • by iData Research, Inc.

The European market for soft tissue reinforcement and regeneration differs substantially from the U.S. market; the European adoption rate of biologics is significantly lower than that of the United States. ...

Sports Medicine: Technologies and Global Markets

Sports Medicine: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • March 2015
  • by BCC Research

REPORT HIGHLIGHTS The global sports medicine market totaled $29.8 billion in 2013 and $31.1 billion in 2014. The market is expected to reach $43.3 billion by 2019, a compound annual growth rate (CAGR) ...

Global Hpv Testing Industry

April 2015 $ 4 950

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.